Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium Butyricum for Anxiety and Depression in Functional Dyspepsia
NCT07182890Phase 4Recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 4 trial of clostridium butyricum in functional dyspepsia (FD), anxiety disorder, major depressive disorder (MDD), sponsored by Xijing Hospital of Digestive Diseases. Started Mar 2026; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
functional dyspepsia (FD)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07182890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182890.